Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 587-597

  Gaudet, Mia M ^a   Press, Michael F ^b   Haile, Robert W ^b   Lynch, Charles F ^c   Glaser, Sally L ^d,e   Schildkraut, Joellen ^f   Gammon, Marilie D ^g   Thompson, W Douglas ^h   Bernstein, Jonine L ⁱ  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d NORTHERN CALIFORNIA CANCER CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f DUKE CANCER INSTITUTE   (United States)

^g IL   (United States)

^h UNIVERSITY OF SOUTHERN MAINE   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Estrogen receptor; HER2; Progesterone receptor; Risk factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BODY SIZE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MULTICENTER STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER;

ADULT; BODY MASS INDEX; BREAST FEEDING; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; YOUNG ADULT;

EID: 82955203450     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1616-x     Document Type: Article

References (46)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Bor-resen-Dale AL (2001) Gene expression patterns of breast carci-nomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874 (Pubitemid 32878711)
2. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7:127. doi:10.1186/1471-2164-7-127 (Pubitemid 44027496)
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, De-ming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21): 2492-2502. doi:10.1001/jama.295.21.2492 (Pubitemid 43854964)
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast can-cer subtypes. Clin Cancer Res 13(8):2329-2334. doi:10.1158/1078-0432.CCR-06-1109 (Pubitemid 46698581)
5. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113(2):357-370. doi:10.1007/s10549-008-9926-3
6. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123-139. doi:10.1007/s10549-007-9632-6 (Pubitemid 351538762)
7. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31. doi:10.1186/bcr2261
8. Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Cartun RW, Mandich D, Sasano H, Evans DB, Sutter TR, Sherman ME (2007) Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 67(21):10608-10617. doi: 10.1158/0008-54 (Pubitemid 350070838)
9. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast can-cer. Cancer 113(7):1521-1526. doi:10.1002/cncr.23786
10. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Body size and risk of luminal, HER2-overexpressing, and triple-nega-tive breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(8):2078-2086. doi:10.1158/1055-9965.EPI-08-0206
11. Anderson WF, Matsuno RK, Sherman ME, Lissowska J, Gail MH, Brinton LA, Yang XR, Peplonska B, Chen BE, Rosenberg PS, Chatterjee N, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Devesa SS, Garcia-Closas M (2007) Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control 18(4):439-447. doi:10. 1007/s10552-006-0092- 9 (Pubitemid 46434789)
12. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopath-ologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1899-1905. doi:10.1158/1055-9965.EPI-06- 0191 (Pubitemid 44664266)
13. Wingo PA, Ory HW, Layde PM, Lee NC (1988) The evaluation of the data collection process for a multicenter, population-based, case-control design. Am J Epidemiol 128(1):206-217
14. Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP (2002) Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 67(9):799-813 (Pubitemid 34765669)
15. Press MF, Greene GL (1984) An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab Invest 50(4): 480-486 (Pubitemid 14136713)
16. Press MF, Hung G, Godolphin W, Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54(10):2771-2777 (Pubitemid 24173773)
17. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of HER-2/neu gene amplification and over-expression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20(14):3095-3105 (Pubitemid 34791099)
18. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18(4):1157-1166. doi:10.1158/1055- 9965.EPI-08-1005
19. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Bio-markers Prev 16(3):439-443. doi:10.1158/1055-9965.EPI-06-0806 (Pubitemid 46548646)
20. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, Mc Donald JA, Press MF, Bernstein L (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 70(2):575-587. doi:10.1158/0008-5472.CAN-09-3460
21. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G (2009) Is there a difference in the association between percent mammo-graphic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18(2):479-485. doi:10.1158/1055-9965.EPI-08-0805
22. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, proges-terone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a popula-tion-based study from the California cancer Registry. Cancer 109(9):1721-1728. doi:10.1002/cncr.22618 (Pubitemid 46668532)
23. Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100(22):1643-1648. doi: 10.1093/jnci/djn344
24. Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Ruschoff J, van de Vijver M (2009) Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 132(4):539-548. doi:10.1309/AJCPV2I0HGPMGBSQ
25. Di Vito KA, Charette LA, Rimm DL, Camp RL (2004) Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84(8):1071-1078. doi:10.1038/labinvest.3700131 (Pubitemid 39025041)
26. Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME (2004) Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13(4):667-672 (Pubitemid 38737907)
27. Sherman ME, Howatt W, Blows FM, Pharoah P, Hewitt SM, Garcia-Closas M (2011) Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Bio-markers Prev 19(4):966-972. doi:10.1158/1055-9965.EPI-10-0056
28. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borre-sen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
29. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemio-logical studies Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347(9017):1713-1727
30. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360(9328):187-195
31. Mc Tiernan A, Thomas DB (1986) Evidence for a protective effect of lactation on risk of breast cancer in young women. Results from a case-control study. Am J Epidemiol 124(3): 353-358 (Pubitemid 16047351)
32. Petrakis NL, Wrensch MR, Ernster VL, Miike R, Murai J, Sim-berg N, Siiteri PK (1987) Influence ofpregnancy and lactation on serum and breast fluid estrogen levels: implications for breast cancer risk. Int J Cancer 40(5):587-591 (Pubitemid 18003843)
33. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z (1996) Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -depen-dentpathways. Development 122(1):181-193 (Pubitemid 26038430)
34. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17-35 (Pubitemid 23269068)
35. Hulka BS, Stark AT (1995) Breast cancer: cause and prevention. Lancet 346(8979):883-887
36. Renehan AG, Roberts DL, Dive C (2008) Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 114(1):71-83. doi:10.1080/13813450801954303 (Pubitemid 351998746)
37. Potischman N, Swanson CA, Siiteri P, Hoover RN (1996) Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 88(11):756-758 (Pubitemid 26195024)
38. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Ko-enig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95(16):1218-1226 (Pubitemid 37069552)
39. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quiros JR, Martinez C, Tormo MJ, Wirfalt E, Berglund G, Hallmans G, Key TJ, Reeves G, Bingham S, Norat T, Biessy C, Kaaks R, Riboli E (2004) Body size and breast cancer risk: findings from the European pro-spective investigation into cancer and nutrition (EPIC). Int J Cancer 111(5):762-771 (Pubitemid 39062901)
40. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007) Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86(3):s858-s866
41. Cleary MP, Grossmann ME (2009) Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150(6): 2537-2542. doi:10.1210/en.2009-0070
42. Stoll BA (2002) Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 26(6):747-753 (Pubitemid 34620865)
43. Cook MG, Rohan TE (1991) Benign breast disease: the rela-tionship between its histological features and risk factors for breast cancer. Pathology 23(4):286-290
44. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482-1485 (Pubitemid 37279334)
45. Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98(23):1675-1677. doi: 10.1093/jnci/djj500 (Pubitemid 44942706)
46. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, Macinnis RJ, Shah M, Search SO, Easton DF, Antoniou AC (2010) Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 12(1):10. doi:10.1186/bcr2476